To include your compound in the COVID-19 Resource Center, submit it here.

argenx reports Phase II myasthenia gravis data for ARX-113

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) reported top-line data from a Phase II study in 24 myasthenia gravis patients showing that 75% of patients treated with efgartigimod

Read the full 257 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE